Effects of 2 Different Duration of Albendazole Therapy in Patients With Neurocysticercosis in Brain ≤ 5 Lesions on CT
NCT ID: NCT02243644
Last Updated: 2016-01-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
97 participants
INTERVENTIONAL
2014-03-31
2015-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Pilot Study of Neurocysticercosis Treatment
NCT00283699
Corticosteroids to Reduce Frequency of Seizures in Neurocysticercosis Patients
NCT00290823
Effect of Albendazole Dose on Clearance of Filarial Worms
NCT00375583
Alternate Chemotherapy Regimens for the Clearance of W.Bancrofti Infection
NCT02005653
A Study to Assess the Efficacy and Safety of Mebendazole for the Treatment of Helminth Infections in Pediatric Participants
NCT02034162
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A
7 days of albendazole 15 mg/kg/day
7 days of albendazole 15 mg/kg/day
group A will receive 7 days of oral albendazole 15 mg/kg/day
Group B
28 days of albendazole 15 mg/kg/day
28 days of albendazole 15 mg/kg/day
group B will receive 28 days of oral albendazole 15 mg/kg/day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
7 days of albendazole 15 mg/kg/day
group A will receive 7 days of oral albendazole 15 mg/kg/day
28 days of albendazole 15 mg/kg/day
group B will receive 28 days of oral albendazole 15 mg/kg/day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Number of parenchymal lesions: upto 5\*
* Stages of cysticerci at which albendazole treatment is effective
* Vesicular stage
* Colloid vesicular stage
* Granular nodular stage
Exclusion Criteria
* Calcified cyst
* Hydrocephalus
* Intraventricular cyst
* Subarachnoid cyst
* Ophthalmic Cysticercosis
* No of cysts \>5
* Known allergy to benzimidazole class of compound which includes anaphylaxis, hypotension, severe skin reactions .
* Features of raised ICT (papilloedema, hyperventilation, hypertension, tonic posturing, B/L 6th nerve palsy, features of midline shift on CT/MRI)
* Critically sick (respiratory failure, cardiovascular instability)
* Already received albendazole or praziquantel or steroid therapy
2 Years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
All India Institute of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sheffali Gulati
Additional professor, dept of Pediatrics
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sheffali Gulati, MD
Role: PRINCIPAL_INVESTIGATOR
AIIMS, New Delhi
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
sheffali Gulati
New Delhi, National Capital Territory of Delhi, India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IESC/T-320/02.08.2013
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.